ERBB2 and gastric cancer: Trastuzumab deruxtecan (T-DXd, DS-8201a, ENHERTU), a representative of the third-generation ADC, has been approved for the treatment of HER2-expressing breast cancer, gastric cancer and HER2 mutant non-small cell lung cancer (NSCLC) [4–7].